Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 61Stomach Neoplasms 10HER2-positive Breast Cancer 7Colorectal Neoplasms 6Neoplasm Metastasis 5Inflammatory Breast Neoplasms 3Breast Diseases 3Brain Neoplasms 3Pathologic Complete Response 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cardiotoxicity 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Relapsed Pediatric Solid Tumor 1Pancreatic Neoplasms 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Invasive Breast Cancer 1Intestinal Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1HER2-positive 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Gastric Cancer 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Feasibility 1Estrogen Receptor-positive Breast Cancer 1

Interventions

pertuzumab 1Vemurafenib 1Trastuzumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Feasibility × Trastuzumab × Clear all
NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Unknown
120 enrolled

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon âš¡